In vitro susceptibility of multidrug-resistant pseudomonas aeruginosa following treatment-emergent resistance to ceftolozane-tazobactam

Abigail M. Rubio; Ellen G. Kline; Chelsea E. Jones; Liang Chen; Barry N. Kreiswirth; M. Hong Nguyen; Cornelius J. Clancy; Vaughn S. Cooper; Ghady Haidar; Daria van Tyne; Ryan K. Shields

doi:10.1128/AAC.00084-21

In vitro susceptibility of multidrug-resistant pseudomonas aeruginosa following treatment-emergent resistance to ceftolozane-tazobactam

Abigail M. Rubio
, Ellen G. Kline
, Chelsea E. Jones
, Liang Chen
, Barry N. Kreiswirth
, M. Hong Nguyen
, Cornelius J. Clancy
, Vaughn S. Cooper
, Ghady Haidar
, Daria van Tyne
, Ryan K. Shields

Pharmacy

University of Pittsburgh
Hackensack Meridian Health
VA Medical Center

Research output: Contribution to journal › Article › peer-review

57 Scopus citations

Abstract

We compared the in vitro susceptibility of multidrug-resistant Pseudomonas aeruginosa isolates collected before and after treatment-emergent resistance to ceftolozane-tazobactam. Median baseline and postexposure ceftolozane-tazobactam MICs were 2 and 64mg/ml, respectively. Whole-genome sequencing identified treatment-emergent mutations in ampC among 79% (11/14) of paired isolates. AmpC mutations were associated with cross-resistance to ceftazidime-avibactam but increased susceptibility to piperacillin-tazobactam and imipenem. A total of 81% (12/16) of ceftolozane-tazobactam-resistant isolates with ampC mutations were susceptible to imipenem-relebactam.

Original language	English
Article number	e00084
Journal	Antimicrobial Agents and Chemotherapy
Volume	65
Issue number	6
DOIs	https://doi.org/10.1128/AAC.00084-21
State	Published - Jun 2021

Keywords

Antibiotic resistance
Ceftolozane-tazobactam
Imipenem-relebactam
Pseudomonas aeruginosa

Access to Document

10.1128/AAC.00084-21

Cite this

Rubio, A. M., Kline, E. G., Jones, C. E., Chen, L., Kreiswirth, B. N., Hong Nguyen, M., Clancy, C. J., Cooper, V. S., Haidar, G., van Tyne, D., & Shields, R. K. (2021). In vitro susceptibility of multidrug-resistant pseudomonas aeruginosa following treatment-emergent resistance to ceftolozane-tazobactam. Antimicrobial Agents and Chemotherapy, 65(6), Article e00084. https://doi.org/10.1128/AAC.00084-21

@article{7585da0f720f4e919cfdbe6ee5061b79,

title = "In vitro susceptibility of multidrug-resistant pseudomonas aeruginosa following treatment-emergent resistance to ceftolozane-tazobactam",

abstract = "We compared the in vitro susceptibility of multidrug-resistant Pseudomonas aeruginosa isolates collected before and after treatment-emergent resistance to ceftolozane-tazobactam. Median baseline and postexposure ceftolozane-tazobactam MICs were 2 and 64mg/ml, respectively. Whole-genome sequencing identified treatment-emergent mutations in ampC among 79\% (11/14) of paired isolates. AmpC mutations were associated with cross-resistance to ceftazidime-avibactam but increased susceptibility to piperacillin-tazobactam and imipenem. A total of 81\% (12/16) of ceftolozane-tazobactam-resistant isolates with ampC mutations were susceptible to imipenem-relebactam.",

keywords = "Antibiotic resistance, Ceftolozane-tazobactam, Imipenem-relebactam, Pseudomonas aeruginosa",

author = "Rubio, \{Abigail M.\} and Kline, \{Ellen G.\} and Jones, \{Chelsea E.\} and Liang Chen and Kreiswirth, \{Barry N.\} and \{Hong Nguyen\}, M. and Clancy, \{Cornelius J.\} and Cooper, \{Vaughn S.\} and Ghady Haidar and \{van Tyne\}, Daria and Shields, \{Ryan K.\}",

year = "2021",

month = jun,

doi = "10.1128/AAC.00084-21",

language = "English",

volume = "65",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "6",

}

Rubio, AM, Kline, EG, Jones, CE, Chen, L, Kreiswirth, BN, Hong Nguyen, M, Clancy, CJ, Cooper, VS, Haidar, G, van Tyne, D & Shields, RK 2021, 'In vitro susceptibility of multidrug-resistant pseudomonas aeruginosa following treatment-emergent resistance to ceftolozane-tazobactam', Antimicrobial Agents and Chemotherapy, vol. 65, no. 6, e00084. https://doi.org/10.1128/AAC.00084-21

TY - JOUR

T1 - In vitro susceptibility of multidrug-resistant pseudomonas aeruginosa following treatment-emergent resistance to ceftolozane-tazobactam

AU - Rubio, Abigail M.

AU - Kline, Ellen G.

AU - Jones, Chelsea E.

AU - Chen, Liang

AU - Kreiswirth, Barry N.

AU - Hong Nguyen, M.

AU - Clancy, Cornelius J.

AU - Cooper, Vaughn S.

AU - Haidar, Ghady

AU - van Tyne, Daria

AU - Shields, Ryan K.

PY - 2021/6

Y1 - 2021/6

N2 - We compared the in vitro susceptibility of multidrug-resistant Pseudomonas aeruginosa isolates collected before and after treatment-emergent resistance to ceftolozane-tazobactam. Median baseline and postexposure ceftolozane-tazobactam MICs were 2 and 64mg/ml, respectively. Whole-genome sequencing identified treatment-emergent mutations in ampC among 79% (11/14) of paired isolates. AmpC mutations were associated with cross-resistance to ceftazidime-avibactam but increased susceptibility to piperacillin-tazobactam and imipenem. A total of 81% (12/16) of ceftolozane-tazobactam-resistant isolates with ampC mutations were susceptible to imipenem-relebactam.

AB - We compared the in vitro susceptibility of multidrug-resistant Pseudomonas aeruginosa isolates collected before and after treatment-emergent resistance to ceftolozane-tazobactam. Median baseline and postexposure ceftolozane-tazobactam MICs were 2 and 64mg/ml, respectively. Whole-genome sequencing identified treatment-emergent mutations in ampC among 79% (11/14) of paired isolates. AmpC mutations were associated with cross-resistance to ceftazidime-avibactam but increased susceptibility to piperacillin-tazobactam and imipenem. A total of 81% (12/16) of ceftolozane-tazobactam-resistant isolates with ampC mutations were susceptible to imipenem-relebactam.

KW - Antibiotic resistance

KW - Ceftolozane-tazobactam

KW - Imipenem-relebactam

KW - Pseudomonas aeruginosa

UR - https://www.scopus.com/pages/publications/85105996989

U2 - 10.1128/AAC.00084-21

DO - 10.1128/AAC.00084-21

M3 - Article

C2 - 33820773

AN - SCOPUS:85105996989

SN - 0066-4804

VL - 65

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 6

M1 - e00084

ER -

In vitro susceptibility of multidrug-resistant pseudomonas aeruginosa following treatment-emergent resistance to ceftolozane-tazobactam

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this